Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Measurable Metastatic TNBC.~* Participants with CA6-positive disease.~* Participants received at least 1 prior chemotherapy regimen but no more than 3 for advanced/metastatic disease.~* Prior anticancer therapy must have contained anthracycline (eg, doxorubicin), if not contraindicated, and a taxane (eg, docetaxel, paclitaxel) in an adjuvant/neo-adjuvant or metastatic setting.~Exclusion criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status \>=2.~* Participant less than 18 years old.~* Pregnant or breast-feeding women.~* Participants with reproductive potential who do not agree to use accepted and effective method of contraception during the study treatment period and for 6 months following discontinuation of study drug.~* Wash out period of less than 3 weeks or 5 half-lives from previous antitumor chemotherapy, immunotherapy, or any investigational treatment.~* History of brain metastasis (other than totally resected or previously irradiated and nonprogressive/relapsed), spinal cord compression or carcinomatous meningitis, or new evidence of brain leptomeningeal disease.~* Prior treatment with eribulin as last prior therapy or prior maytansinoid treatments (DM1 or DM4 antibody-drug conjugates \[ADCs\]).~* Known intolerance to infused protein products including other monoclonal antibodies and ADCs.~* Poor bone marrow reserve and/or poor organ function.~* Symptomatic peripheral neuropathy Grade \>=2.~* Previous history of chronic corneal diseases (even if asymptomatic) or unresolved acute nonrecurrent corneal conditions.~* Participants wearing contact lenses who are not willing to stop wearing them for the duration of the study.~* Medical conditions requiring concomitant administration of strong Cytochrome P450 3A4 (CYP3A4) inhibitors, unless it could be discontinued at least 2 weeks before 1st administration of SAR566658.~* Contraindications to the use of ophthalmic vasoconstrictor and/or corticosteroid.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SAR566658 90 mg/m^2 (Type: EXPERIMENTAL): Participants received SAR566658 90 milligram per square meter (mg/m\^2) as intravenous infusion on Day 1 and Day 8 of each 21-day treatment cycle (maximum number of cycles received was 3).
- SAR566658 120 mg/m^2 (Type: EXPERIMENTAL): Participants received SAR566658 120 mg/m\^2 as intravenous infusion on Day 1 and Day 8 of each 21-day treatment cycle (maximum number of cycles received was 3).

Based on this trial design, predict the completion outcome and termination type (if applicable).